AR133317A1 - Constructos antigénicos de porphyromonas gingivalis - Google Patents
Constructos antigénicos de porphyromonas gingivalisInfo
- Publication number
- AR133317A1 AR133317A1 ARP240101906A ARP240101906A AR133317A1 AR 133317 A1 AR133317 A1 AR 133317A1 AR P240101906 A ARP240101906 A AR P240101906A AR P240101906 A ARP240101906 A AR P240101906A AR 133317 A1 AR133317 A1 AR 133317A1
- Authority
- AR
- Argentina
- Prior art keywords
- kgp
- gingivalis
- porphyromonas gingivalis
- polypeptide
- adhesin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22037—Gingipain R (3.4.22.37)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22047—Gingipain K (3.4.22.47)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Esta invención se refiere a composiciones (p. ej., composiciones de vacunas) que se pueden utilizar para inmunizar contra infecciones por P. gingivalis. Las composiciones comprenden antígenos de P. gingivalis y combinaciones de antígenos que se pueden utilizar para inmunizar contra P. gingivalis, que se utilizan en forma de ácidos nucleicos (p. ej., ARNm) que codifican proteínas antigénicas o en forma de antígenos de proteínas recombinantes. Reivindicación 1: Un ácido nucleico que comprende una secuencia de nucleótidos que codifica un polipéptido, en donde el polipéptido comprende: i) al menos una porción de un dominio catalítico de proteinasa específica de Lys (Kgp) de Porphyromonas gingivalis; ii) al menos una porción de un dominio de Kgp de Porphyromonas gingivalis de función desconocida 2436 (DUF2436); iii) al menos una porción de un dominio de adhesina K1 de Kgp de Porphyromonas gingivalis; iv) una primera porción de Kgp de Porphyromonas gingivalis que comprende un motivo 1 de unión a adhesina (ABM1) y una primera porción de Kgp de Porphyromonas gingivalis que comprende un motivo 2 de unión a adhesina (ABM2); v) una segunda porción de Kgp de Porphyromonas gingivalis que comprende un ABM1 y una segunda porción de Kgp de Porphyromonas gingivalis que comprende un ABM2; y vi) una porción de Kgp de Porphyromonas gingivalis que comprende un motivo 3 de unión a adhesina (ABM3). Reivindicación 22: Un polipéptido como se define en cualquiera de las reivindicaciones 1 - 20. Reivindicación 23: Una composición que comprende el ácido nucleico de una cualquiera de las reivindicaciones 1 - 21, o el polipéptido de la reivindicación 22, preferentemente en donde la composición es una composición inmunogénica. Reivindicación 30: Una vacuna que comprende el ácido nucleico de una cualquiera de las reivindicaciones 1 - 21, el polipéptido de la reivindicación 22 o la composición de una cualquiera de las reivindicaciones 23 - 27.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23306245 | 2023-07-19 | ||
| EP23307238 | 2023-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133317A1 true AR133317A1 (es) | 2025-09-17 |
Family
ID=92043339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101906A AR133317A1 (es) | 2023-07-19 | 2024-07-19 | Constructos antigénicos de porphyromonas gingivalis |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR133317A1 (es) |
| TW (1) | TW202517779A (es) |
| WO (1) | WO2025017202A2 (es) |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| CA2560114A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| EP1039935A4 (en) | 1997-02-28 | 2005-04-27 | Univ Iowa Res Found | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| ATE370740T1 (de) | 1997-05-20 | 2007-09-15 | Ottawa Health Research Inst | Verfahren zur herstellung von nukleinsäurekonstrukten |
| CA2323929C (en) | 1998-04-03 | 2004-03-09 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| ATE420965T1 (de) | 2004-05-18 | 2009-01-15 | Alphavax Inc | Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren |
| WO2010022463A1 (en) * | 2008-08-29 | 2010-03-04 | Oral Health Australia Pty Ltd | Prevention, treatment and diagnosis of p.gingivalis infection |
| CA2766907A1 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| BR112012002429A2 (pt) | 2009-08-02 | 2016-11-08 | Sanofi Pasteur Ltd | polipeptídeos de porphyromonas gingivalis |
| CA2782676C (en) | 2009-12-01 | 2021-06-15 | Shire Human Genetic Therapies, Inc. | Pharmaceutical compositions for intracellular delivery of nucleic acids and proteins and uses thereof for treatment of ureca cycle metabolic disorders |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| CA3107288A1 (en) | 2011-06-08 | 2012-12-13 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| EP4074694A1 (en) | 2011-10-27 | 2022-10-19 | Massachusetts Institute Of Technology | Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof |
| JP6561378B2 (ja) | 2012-06-08 | 2019-08-21 | トランスレイト バイオ， インコーポレイテッド | 非肺標的細胞へのｍＲＮＡの経肺送達 |
| ES2680595T3 (es) | 2013-03-14 | 2018-09-10 | Translate Bio, Inc. | Evaluación cuantitativa para eficacia de ARN mensajero para tapar |
| HUE071526T2 (hu) | 2013-03-15 | 2025-09-28 | Translate Bio Inc | Nukleinsavak bejuttatásának szinergista fokozása kevert kiszerelésekkel |
| CN105451779A (zh) | 2013-08-21 | 2016-03-30 | 库瑞瓦格股份公司 | 增加rna编码蛋白表达的方法 |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
| CN105874072A (zh) | 2013-12-30 | 2016-08-17 | 库瑞瓦格股份公司 | 人工核酸分子 |
| CN114146063A (zh) | 2014-07-02 | 2022-03-08 | 川斯勒佰尔公司 | 信使rna的包封 |
| DK3708668T3 (da) | 2014-12-12 | 2022-09-26 | Curevac Ag | Kunstigt nukleinsyremolekyle til forbedret proteinudtrykkelse |
| EP3289101B1 (en) | 2015-04-30 | 2021-06-23 | CureVac AG | Immobilized poly(n)polymerase |
| EP4248988A3 (en) | 2015-06-19 | 2023-11-29 | Massachusetts Institute of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| US20180153822A1 (en) | 2016-11-10 | 2018-06-07 | Translate Bio, Inc. | Process of Preparing mRNA-Loaded Lipid Nanoparticles |
| AU2017357748B2 (en) | 2016-11-10 | 2023-11-09 | Translate Bio, Inc. | Improved ice-based lipid nanoparticle formulation for delivery of mRNA |
| JP2023547197A (ja) | 2020-10-28 | 2023-11-09 | サノフィ・パスツール | Ｔｌｒ４アゴニストを含有するリポソーム、その製造および使用 |
| TW202309002A (zh) | 2021-04-15 | 2023-03-01 | 美商轉譯生技公司 | 基於「古德」緩衝液的陽離子脂質 |
-
2024
- 2024-07-19 AR ARP240101906A patent/AR133317A1/es unknown
- 2024-07-19 TW TW113127242A patent/TW202517779A/zh unknown
- 2024-07-19 WO PCT/EP2024/070627 patent/WO2025017202A2/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025017202A3 (en) | 2025-05-30 |
| TW202517779A (zh) | 2025-05-01 |
| WO2025017202A2 (en) | 2025-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014070A (es) | Composiciones y metodos de arn circular. | |
| PE20230301A1 (es) | Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion | |
| AR076349A1 (es) | Peptido auxiliar del antigeno del cancer | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| SI2280721T1 (en) | Indoleamine 2, 3-dioxygenase based immunotherapy | |
| PE20210376A1 (es) | Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
| AR008588A1 (es) | Molecula de acido nucleico aislada que hibridiza con un gen de saliva de pulga, proteina aislada codificada por dicha molecula, composicion terapeuticapara tratar la dermatitis alergica, kit de ensayo para determinar dicha dermatitis, molecula, virus y celula recombinantes, y anticuerpo aislado | |
| PE20250020A1 (es) | Composicion inmunogenica contra la influenza | |
| AR085167A1 (es) | Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit | |
| PE20241187A1 (es) | Moleculas de arn | |
| CO5580165A1 (es) | Vacunas de rotavirus modificado | |
| PE20230783A1 (es) | Proteinas actrii para el tratamiento de la hipertension pulmonar | |
| CO2021017664A2 (es) | Péptidos | |
| MX2024004296A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
| AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
| ECSP024257A (es) | Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas | |
| CO2025013415A2 (es) | Composiciones para su uso en el tratamiento de clamidia | |
| AR056133A1 (es) | Virus de influenza canina y composiciones relacionadas y metodos de uso | |
| AR133317A1 (es) | Constructos antigénicos de porphyromonas gingivalis | |
| AR124522A1 (es) | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEÍNA SPIKE DEL SARS-CoV-2 | |
| BR112022026248A2 (pt) | Conjugados de citocinas | |
| AR028713A1 (es) | Inmunizacion de ganado productor de leche con proteinas gapc quiméricas contra infecciones por streptococcus | |
| CO2019005169A2 (es) | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus |